Cas:863307-54-4 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid manufacturer & supplier

Chemical Name:2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid

CAS.NO:863307-54-4

Synonyms:2-carboxymethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester

Molecular Formula:C₁₁H₁₈N₂O₅

Molecular Weight:258.27100

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:95.94000

Exact Mass:258.12200

LogP:0.46330

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-carboxymethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-carboxymethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-carboxymethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester Use and application,2-carboxymethyl-3-oxo-piperazine-1-carboxylic acid tert-butyl ester technical grade,usp/ep/jp grade.

Related News: Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid manufacturer Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations. 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid supplier Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid vendor Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3-oxopiperazin-2-yl]acetic acid factory In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being.